***PKTX.. This is what it is All about in a Nut Sh
Post# of 88
Posted On: 09/15/2016 12:17:29 PM
***PKTX.. This is what it is All about in a Nut Shell.. :+O
..ProtoKinetix’ Summary of Their Glyco Peptide (AAGP™) Molecule Development
...Over 10-years ago, ProtoKinetix (PKTX) commissioned INSA (French National Institute of Applied Science) to produce a small, stable, synthetic glyco peptide using their gem diflouride platform. The molecule selected was a mimic of a well characterized, glyco protein known as Anti-Freeze Glyco Protein (AFGP). The lead scientist from INSA was Dr. Geraldine Deliencourt.
..During this period of time ProtoKinetix was working of the molecule, a new medical initiative arose from theory to maturity through extensive research conducted on stem cells. This field of research is collectively known as “regenerative medicine”. Regenerative medicine attempts to replace damaged cells or tissues as an effective therapy for a wide range of diseases and conditions such as nerve damage, lung damage, heart damage, etc. ProtoKinetix’ role here is the protection of these cells before, during and after the procedure.
..Under the terms of the original INSA commission, ProtoKinetix paid for the proof of concept in exchange for the worldwide exclusive rights to the family of AFGP molecules. Subsequently, ProtoKinetix has conducted extensive testing on cell preservation and anti-inflammation resulting in substantial data allowing the Company to file patents. To date, the patents have been granted for the United States, Europe and Canada.
..In 2014, PKTX filed for a series of new patents based on results generated by the University of Alberta trials. These are brand new applications protected by worldwide provisional patents.
The Company has completed a series of mechanism of action studies, showing how the molecule achieves its effect of inhibiting inflammation and protecting cells from premature death. This data will enable PKTX to more clearly identify the optimal therapeutic uses for disease.
..Stem cell research has demonstrated major benefits of using AAGP™ during the following stages:
1. Freeze/thaw recovery (cryopreservation)
2. Primary differentiation
3. Migration to progenitor status (precursor cells)
4. Transplantation
5. Engraftment
6. Protection against anti-rejection drugs
..ProtoKinetix’ Summary of Their Glyco Peptide (AAGP™) Molecule Development
...Over 10-years ago, ProtoKinetix (PKTX) commissioned INSA (French National Institute of Applied Science) to produce a small, stable, synthetic glyco peptide using their gem diflouride platform. The molecule selected was a mimic of a well characterized, glyco protein known as Anti-Freeze Glyco Protein (AFGP). The lead scientist from INSA was Dr. Geraldine Deliencourt.
..During this period of time ProtoKinetix was working of the molecule, a new medical initiative arose from theory to maturity through extensive research conducted on stem cells. This field of research is collectively known as “regenerative medicine”. Regenerative medicine attempts to replace damaged cells or tissues as an effective therapy for a wide range of diseases and conditions such as nerve damage, lung damage, heart damage, etc. ProtoKinetix’ role here is the protection of these cells before, during and after the procedure.
..Under the terms of the original INSA commission, ProtoKinetix paid for the proof of concept in exchange for the worldwide exclusive rights to the family of AFGP molecules. Subsequently, ProtoKinetix has conducted extensive testing on cell preservation and anti-inflammation resulting in substantial data allowing the Company to file patents. To date, the patents have been granted for the United States, Europe and Canada.
..In 2014, PKTX filed for a series of new patents based on results generated by the University of Alberta trials. These are brand new applications protected by worldwide provisional patents.
The Company has completed a series of mechanism of action studies, showing how the molecule achieves its effect of inhibiting inflammation and protecting cells from premature death. This data will enable PKTX to more clearly identify the optimal therapeutic uses for disease.
..Stem cell research has demonstrated major benefits of using AAGP™ during the following stages:
1. Freeze/thaw recovery (cryopreservation)
2. Primary differentiation
3. Migration to progenitor status (precursor cells)
4. Transplantation
5. Engraftment
6. Protection against anti-rejection drugs
(0)
(0)ProtoKinetix, Inc. (PKTX) Stock Research Links
Scroll down for more posts ▼